Topics

ESO-ESMO 4 International Consensus Guidelines for Breast Cancer in Young Women (BCY4).

08:00 EDT 18th March 2020 | BioPortfolio

Summary of "ESO-ESMO 4 International Consensus Guidelines for Breast Cancer in Young Women (BCY4)."

The 4 International Consensus Conference for Breast Cancer in Young Women (BCY4) took place in October 2018, in Lugano, Switzerland, organized by the European School of Oncology (ESO) and the European Society of Medical Oncology (ESMO). Consensus recommendations for the management of breast cancer in young women were updated from BCY3 with incorporation of new evidence to inform the guidelines. Areas of research priorities were identified as well. This manuscript summarizes the ESO-ESMO international consensus recommendations, which are also endorsed by the European Society of Breast Specialists (EUSOMA).

Affiliation

Journal Details

This article was published in the following journal.

Name: Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Pages:

Links

DeepDyve research library

PubMed Articles [32462 Associated PubMed Articles listed on BioPortfolio]

Breast cancer in young black women.

Young age at breast cancer diagnosis is associated with negative prognostic outcomes, and breast cancer in black women often manifests at a young age. This study evaluated the effect of age on breast ...

A population-based cohort of young women diagnosed with breast cancer in Geneva, Switzerland.

Breast cancer is the most frequently diagnosed cancer among women worldwide. Despite the fact that breast cancer is more frequent after fifty years of age, breast cancer among young women has recently...

Young Woman in the Breast Clinic: Ultrasound or Not?

Young women concerned about a breast cancer diagnosis will visit breast care centers and request breast cancer screening, including imaging studies, on their initial visit.

What attitude to women at high risk of breast cancer?

In France, breast cancer is the most common cancer among women and the leading cause of cancer deaths. Identifying women with a "high" or "very high" breast cancer risk, according the terminology of t...

Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.

Breast cancer is the most common nonskin cancer among women in the United States and the second leading cause of cancer death. The median age at diagnosis is 62 years, and an estimated 1 in 8 women wi...

Clinical Trials [25888 Associated Clinical Trials listed on BioPortfolio]

Genotype and Phenotype in Early Onset Breast Cancer in Young Women on the Two Shores of the Mediterranean Sea

Breast cancer are common on mediterranean basin. Epidemiological data suggest that breast cancer in young women (< 40years old) is more aggressive in the Maghreb countries comparatively t...

Young Women's Breast Cancer Research Program

The purpose of this study is to identify novel genetic factors which distinguish breast cancer in younger women compared to older women. By identifying these novel genetic factors we belie...

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Breast cancer is the most frequent neoplasm in women in Brazil and in the world and up to 15% of all cases diagnosed correspond to the triple negative subtype. Triple negative breast cance...

Improving Surgical Decision-making in Young Women With Breast Cancer

The overall goal of this study is to qualitatively assess the surgical decision-making process from both the patient and physician perspective 1. Conduct short in-person interviews with...

Awareness About Breast Cancer Screening

Breast cancer is the most common cancer in French women, with 52000 new cases each year. Shift work and night work is recognized by International Agency for Research on Cancer as a potent...

Medical and Biotech [MESH] Definitions

A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.

A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)

A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.

Quick Search


DeepDyve research library

Relevant Topics

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...


Searches Linking to this Article